Outcome of Board Meeting held on May 29, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2025. Standalone revenue rose modestly to Rs. 141.96 crore from Rs. 138.33 crore, while net profit more than doubled to Rs. 5.12 crore from Rs. 2.29 crore, lifting EPS to Rs. 14.71 from Rs. 5.16. Auditor Kailash Chand Jain & Co. issued an unmodified (clean) opinion. The Board also re-appointed Shri Sanjay Kedia (Chartered Accountant, 26 years in chemicals) as Whole-time Director for three years effective November 8, 2025, subject to shareholder approval, and appointed M/s Parikh Parekh & Associates as Secretarial Auditor for five years (FY 2025-26 to FY 2029-30). The company confirmed NIL deviation in the use of Rs. 6.57 crore raised via preferential issue in November 2024.
Profitability improvement is a clear positive for shareholders, but the sharp drop in Q4 standalone net profit to just Rs. 2.49 lakh (vs Rs. 264.71 lakh in Q3) and negative operating cash flow (-Rs. 1.48 crore standalone) suggest weakness in the final quarter worth watching. Continuity in the Whole-time Director role and a clean audit opinion support stability.